Patients receive pyroxamide IV continuously over 5-7 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

HCT116 cells were used for activity evaluation. Cells were plated in 96-well plates at initial densities of between 1000 and 3000 cells/well and incubated. After 24 h, test compound 7c (Pyroxamide) were added to test wells, vehicle added to vehicle control (VC) wells and initial growth control wells (IGC) received 10 µL 3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) mixture (prepared on day of use at a ratio of 10 µL of a 0.92 mg/mL solution of phenazine methosulfate (PMS) to a 190 µL of a 2 mg/mL solution of MTS), the plate was incubated for 4 h and the OD490 of IGC wells was measured on a Molecular Devices Thermomax at 490 nm using the Softmax program to determine initial cell density values. The plates were incubated for 72 h, 10 µL/well of MTS mixture was added to the test and VC wells and the OD490 was measured.